SCHEMBL2530876

SCHEMBL2530876

CS(=O)(=O)c1cccc(-c2cc(-c3c[nH]c4ncccc34)cc(=O)[nH]2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 8/20 0.49
DBF4 Q9UBU7 4/20 0.49
CAMKK2 Q96RR4 2/20 0.48
ROCK2 O75116 3/20 0.47
MAP4K4 O95819 3/20 0.47
PIM1 P11309 3/20 0.47
PRKACA P17612 3/20 0.47
CDK2 P24941 3/20 0.47
GSK3B P49841 3/20 0.47
HIPK2 Q9H2X6 3/20 0.47
CLK4 Q9HAZ1 3/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
DYRK1A Q13627 4/20 0.46
ROCK1 Q13464 2/20 0.45
CYP3A4 P08684 1/20 0.45
BRD4 O60885 1/20 0.45
PIK3C3 Q8NEB9 2/20 0.44
JAK3 P52333 3/20 0.44
DAPK3 O43293 2/20 0.44
PRKD3 O94806 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2527234 0.83 CDC7 (0.63) CDC7DBF4CAMKK2ROCK2MAP4K4
SCHEMBL2528996 0.83 CDC7 (0.55) CDC7DBF4CAMKK2ROCK2MAP4K4
SCHEMBL2525016 0.80 CDC7 (0.54) CDC7DBF4CAMKK2ROCK2MAP4K4
SCHEMBL27914520 0.80 CDC7 (0.54) CDC7DBF4CAMKK2ROCK2MAP4K4
SCHEMBL2529127 0.80 CDC7 (0.51) CDC7DBF4ROCK2MAP4K4PIM1
SCHEMBL2528301 0.79 CDC7 (0.56) CDC7DBF4CAMKK2ROCK2MAP4K4
SCHEMBL2526405 0.78 DYRK1A (0.55) CDC7DBF4CAMKK2ROCK2MAP4K4
SCHEMBL2531750 0.78 DYRK1A (0.53) CDC7DBF4ROCK2MAP4K4PIM1
SCHEMBL2534917 0.78 DYRK1A (0.54) CDC7DBF4CAMKK2ROCK2MAP4K4
SCHEMBL2527494 0.77 PIK3C3 (0.56) CDC7DBF4CAMKK2ROCK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822446-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2014-09-02 US claimed
EP-2560971-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-02-27 EP claimed
WO-2011133388-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-27 WO claimed
US-20110257152-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-20 US claimed
US-9181246-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2015-11-10 US disclosed
US-20140357616-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2014-12-04 US disclosed
US-8822446-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2014-09-02 US disclosed
CN-103003274-A Pyrrolopyridine inhibitors of kinases ABBVIE INC 2013-03-27 CN disclosed
EP-2560971-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-02-27 EP disclosed
WO-2011133388-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-27 WO disclosed
US-20110257152-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357616-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885DBF4 2301/4885CAMKK2 489/4885
US-20110257152-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885DBF4 2301/4885CAMKK2 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.